

CURRICULUM VITAE

GIULIA RENDA

Giulia Renda, MD, PhD

Associate Professor in Cardiology
Department of Neurosciences, Imaging and Clinical Sciences
Experimental Cardiology – CAST
G. d'Annunzio University, Chieti-Pescara
via L. Polacchi 11, 66100 Chieti – tel 0871-541385, fax 0871-541386
Institute of Cardiology - SS. Annunziata Hospital, Chieti
Via dei Vestini 31, 66100 Chieti - tel. 0871-41512, fax: 0871-402817
E-mail: giulia.renda@unich.it



<http://orcid.org/0000-0002-4770-8386>

PRESENT POSITION

Associate Professor in Cardiology – Department of Neurosciences, Imaging and Clinical Sciences – G. d'Annunzio University, Chieti-Pescara

EDUCATION

- 1990: **Diploma at High School**, Classic Lycée G. B. Vico, Chieti
- 1996: **Degree in Medicine**, School of Medicine, G. d'Annunzio University, Chieti
- 1997: **Italian Board Certification** - G. d'Annunzio University, Chieti
- 1998: **Italian National Board of Medicine**, Board of Chieti (Italy) – Registration n. 3892
- 2001: **Postgraduate in Cardiology** - Institute of Cardiology, Catholic University of the Sacred Heart, Roma
- 2005: **PhD in Biomedical Technologies and Functional Bioimaging** - Institute of Cardiology, Department of Neurosciences and Imaging, G. d'Annunzio University, Chieti
- 2005-2008: **Post-doctoral research grant** - Institute of Cardiology, Department of Neurosciences and Imaging, G. d'Annunzio University, Chieti
- 2008-2009: **Master in Pediatric Cardiology** - Department of Pediatric Cardiology, University of Bologna
- 2008-2019: **Assistant Professor in Cardiology** - Department of Neurosciences, Imaging and Clinical Sciences, Section of Cardiovascular and Pharmacological Sciences – G. d'Annunzio University, Chieti-Pescara
- 2019- present: **Associate Professor in Cardiology** - Department of Neurosciences, Imaging and Clinical Sciences, Section of Cardiovascular and Pharmacological Sciences – G. d'Annunzio University, Chieti-Pescara

RESEARCH APPOINTMENTS

- 1991-1993: Institute of Human Morphology, G. d'Annunzio University, Chieti.
Project on: cellular biochemistry and molecular biology of lymphoid cell differentiation.
- 1995: Institute of Physiopathologie cellulaire et moléculaire des cellules du sang et du vaisseau, INSERM Unit 348, Paris.
Project on: quantitative evaluation of cyclooxygenase-2 in endothelial cells.
- 1995-1997: Institute of Pharmacology, Laboratory of Cardiovascular Research, G. d'Annunzio University, Chieti.
Main area of interest and projects on: i) pharmacological modulation of cyclooxygenase-1 and 2; ii) expression and pharmacological modulation of cyclooxygenase in patients with ischemic heart disease.
- 1997-2001: Institute of Cardiology, Catholic University of the Sacred Heart, Roma.
Main area of interest and projects on: i) aspirin resistance, in collaboration with Institute of Pharmacology, G. d'Annunzio University, Chieti; ii) influence of fibrinogen concentration and platelet count on the inhibitory effect of glycoprotein IIb/IIIa inhibitors, in collaboration with Institute of Hematology, Catholic University of the Sacred Heart, Roma.
- 2001- present: Institute of Cardiology, Department of Neuroscience, Imaging and Clinical Sciences - G. d'Annunzio University, Chieti-Pescara
Coordinator of Experimental Cardiology Lab – Laboratory of Systems Pharmacology and Translational Therapeutics (SPATTLAB, P.I. Prof. Paola Patrignani) - Center for Advanced Studies and Technology (CAST), G. d'Annunzio University, Chieti - Pescara

Main area of interest and projects on:

- Hemostasis and thrombosis, platelet aggregation
- Antithrombotic therapy in cardiovascular disease: i) clinical pharmacology of antiplatelet and anticoagulant drugs; ii) antiplatelet effects of non-vitamin K antagonist oral anticoagulants (NOACs)
- Atrial fibrillation: i) antithrombotic therapy in atrial fibrillation; ii) efficacy and safety of NOACs in different clinical setting; iii) prognostic value of CHA₂DS₂VASc score for new-onset atrial fibrillation, cardiovascular morbidity and mortality; iv) relationship between atrial fibrillation and cryptogenic stroke
- Pressure variability and organ damage
- Nutrigenetic of coffee

Participation in International Clinical Trials

- 13 Phase III Clinical Trials - Sub-investigator
- 6 Observational Studies - Principal Investigator (3) or Sub-investigator (3)
- Co-author of many related analyses

Collaboration with international research groups:

- **TIMI Study Group - Boston, MA (USA)**
Projects and analyses on: i) efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation undergoing cardioversion; ii) efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease
- **Team in AF (Thrombosis ExchAnge prograM): European research group on atrial fibrillation**
Projects and analyses on: i) PREvention of thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF); ii) European Multinational Prolongation Registry on Prevention of Thromboembolic Events in Atrial Fibrillation (PREFER in AF prolongation); iii) Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (ETNA-AF)

- **Research group of Malmo Lund University** (Professor Artur Fedorowski), Sweden
Projects and analyses on: i) prognostic value of CHA₂DS₂VASc score for new-onset atrial fibrillation, cardiovascular morbidity and mortality; ii) platelet indices and risk of death and cardiovascular events; iii) clustering of anemia, leukocytosis and thrombocytosis as a risk marker for death and future cardiovascular events

Participation in Working Groups of Cardiology Societies

- Working Group on Thrombosis of European Society of Cardiology
- Working Group on Thrombosis of Italian Society of Cardiology – **Working Group Coordinator 2017-2018**

Projects Funded by public national and international entities

- **PRIN: 2009L4X28T_002** – Area 06. Title: Prognostic implications of lymphocytic G-protein coupled receptor kinase-2 modifications induced by β -blocker therapy in patients with heart failure. Scientific Coordinator: Prof. Dario Leosco. Principal Investigator: Prof. F. Cipollone. Role: Participant. Duration: 24 months

Awards and recognitions

- August 2007: Thrombosis Young Investigators' Award – ESC Congress 2007
Abstract: "Lack of correlation between different methods assessing ex vivo platelet function in aspirin-treated patients - relevance for the definition of aspirin resistance". Renda G, Rocca B, Zurro M, De Cristofaro R, De Caterina R. Eur Heart J 2007; 28 (Abstract Supplement):127.
- April 2016: Highest ranking abstract that was accepted from Italy – American College of Cardiology Annual Scientific Session 2016
Abstract: "Outcomes in 2824 Patients With Valvular Heart Disease Treated With Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial". Renda G, De Caterina R, Carnicelli A, Nordio F, Mercuri M, Ruff C, Giugliano R. Journal of the American College of Cardiology 67(13):2194.

Memberships in Scientific Societies

- Member of Italian Society of Cardiology – **President of Abruzzo-Molise Section 2019-2020**
- Member of European Society of Cardiology
- Member of Italian Society of Haemostasis and Thrombosis
- Member of Study Group of Atherosclerosis Thrombosis and Vascular Biology

Editorial Activity

- Reviewer for the following international scientific journals: i) European Heart Journal, ii) Journal of the American College of Cardiology, iii) International Journal of Cardiology, iv) Vascular pharmacology, v) Clinical Cardiology, vi) Europace, vii) Heart, viii) Journal of Cardiovascular Medicine
- Member of Abstract Reviewing Committee for European Society of Cardiology Congress (2018, 2019, 2020)

Participation in many national and international congresses in cardiologic area as invited speaker

ACADEMIC APPOINTMENTS

Teaching in degree courses – G. d'Annunzio University, Chieti-Pescara:

- Medicine and Surgery
- Nursing
- Cardiocirculatory and cardiovascular perfusion techniques
- Health assistance

Teaching in postgraduate courses – G. d'Annunzio University, Chieti-Pescara:

- Cardiology
- Pediatrics
- Nephrology
- Anesthesiology and Intensive Care
- Sports Medicine

Teaching in First Level Master on Palliative Care and Pain Therapy 2016-2017 – Nursing degree course – G. d'Annunzio University, Chieti-Pescara

Member of the Academic Board of the PhD Course in Medical Biotechnology [DOT1353500] - 2015-2017 – G. d'Annunzio University, Chieti-Pescara

Involvement in training of undergraduate students in Medicine, post-graduate students in Cardiology and PhD students

CLINICAL APPOINTMENTS

2001- present: **Cardiology Service and Outpatient Clinic** – Cardiology Unit, SS. Annunziata Hospital, Chieti

PUBLICATIONS

Peer reviewed Publications in International Journals ranked in the journal citation reports

1. Patrignani P, Panara MR, Sciulli MG, Santini G, **Renda G**, Patrono C. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. *J Physiol Pharmacol* 1997;48(4):623-631
2. Patrono C, **Renda G**. Platelet activation and inhibition in unstable coronary syndromes. *Am J Cardiol* 1997;80(5A):17E-20E.
3. Panara MR, Padovano R, Sciulli MG, Santini G, **Renda G**, Rotondo MT, Pace A, Patrono C, Patrignani P. Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings. *Clin Pharmacol Ther* 1998;63(6):672-681
4. Panara MR, **Renda G**, Sciulli MG, Santini G, Di Giamberardino M, Rotondo MT, Tacconelli S, Seta F, Patrono C, Patrignani P. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. *J Pharmacol Exp Ther* 1999;290(1):276-280
5. Andreotti F, De Luca L, **Renda G**, Ferro A, Mongiardo R, Zecchi P, Maseri A. Circadianicity of hemostatic function and coronary vasomotion. *Cardiologia* 1999;44(Suppl. 1):245-249. Review
6. Niccoli G, **Renda G**, Cianflone D, Crea F. Transient microvascular vasoconstriction: a possible cause of unstable angina. *Ital Heart J* 2000 May;1(5):365-367
7. **Renda G**, Rocca B, Crocchiolo R, De Cristofaro R, Landolfi R. Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban. *Thromb Haemost* 2003;89:348-354
8. **Renda G**, Sciartilli A, De Caterina R. Aspirin Resistance. *Haematologica* 2003;88(suppl.4):43-49
9. Volpe S, Marrone G, **Renda G**, Spina R, Gallina S, Marchetti A, Paloscia L, Di Giammarco G, Calafiore A, De Caterina R. Images in cardiovascular medicine. Membrane-type subaortic stenosis in the adult. *Ital Heart J* 2003 Sep;4(9):651-2
10. Zimarino M, **Renda G**, Maddestra N, De Caterina R. Late coronary thrombosis after drug-eluting stent: stent vs patient-driven prescription of aspirin-clopidogrel combination. *Thromb Haemost* 2004; 92:668-9.
11. Zimarino M, **Renda G**, De Caterina R. Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents. *Drugs* 2005;65(6):725-732

12. Capone, ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, **Renda G**, Di Gregorio P, Merciaro G, Patrignani P. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005;45:1295–301.
13. Zimarino M, Ausiello A, Contegiacomo G, Ricciardi I, **Renda G**, Di Iorio C, De Caterina R. Rapid decline of collateral circulation increases susceptibility to myocardial ischemia. The trade-off of successful percutaneous recanalization of chronic total occlusions. J Am Coll Cardiol 2006;48:59–65.
14. Sciulli MG, **Renda G**, Capone ML, Tacconelli S, Ricciotti E, Manarini S, Evangelista V, Rebuzzi A, Patrignani P. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease. Clin Pharmacol Ther 2006;80:115-25.
15. **Renda G**, Tacconelli S, Capone ML, Sacchetta D, Santarelli F, Sciulli MG, Zimarino M, Grana M, D'Amelio E, Zurro M, Price TS, Patrono C, De Caterina R, Patrignani P. Celecoxib, ibuprofen and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther 2006;80:264-74.
16. **Renda G**, Di Pillo R, D'Alleva A, Sciarilli A, Zimarino M, De Candia E, Landolfi R, Di Giammarco G, Calafiore A, De Caterina R. Surgical bleeding after preoperative unfractionated heparin and low molecular weight heparin at coronary bypass surgery. Haematologica 2007;92:366-373.
17. Tatasciore A, **Renda G**, Zimarino M, Soccio M, Bilo G, Parati G, Schillaci G, De Caterina R. Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. Hypertension 2007;50:325-332.
18. Zimarino M, **Renda G**, De Caterina R. Triple antithrombotic therapy with aspirin, clopidogrel and warfarin – a persisting dilemma. Intern Emerg Med 2007;2:163-64.
19. Patrignani P, **Renda G**, Tacconelli S, Capone ML, Sacchetta D, Santarelli F, Sciulli MG, Zimarino M, Grana M, D'Amelio E, Zurro M, Patrono C, De Caterina R. Response to Pharmacodynamic interaction between aspirin and ibuprofen: a plausible mechanism of aspirin resistance. Clin Pharmacol Ther 2008;83:812-813.
20. Zimarino M, Sacchetta D, **Renda G**, De Caterina R. Facilitated PCI: rationale, current evidence, open questions, and future directions. J Cardiovasc Pharmacol 2008;51:3-10.
21. Tatasciore A, Zimarino M, **Renda G**, Zurro M, Soccio M, Prontera C, Emdin M, Flacco M, Schillaci G, DE Caterina R. Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension. Hypertens Res 2008;31(12):2137-46.
22. De Caterina R, Kristensen SD and **Renda G**. New anticoagulants for atrial fibrillation. J Cardiovasc Med 2009;10:446–453.
23. De Caterina R, Connolly SJ, Pogue J, Chrolavicius S, Budaj A, Morais J, **Renda G**, Yusuf S; ACTIVE Investigators. Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. Eur Heart J 2010;31(17):2133-40.
24. **Renda G**, Zurro M, Romano M, De Caterina R. Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors. Br J Clin Pharmacol 2010;69(3):303-6.
25. **Renda G**, Zurro M, Malatesta G, Ruggieri B, De Caterina R. Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance. Haematologica 2010;95(12):2095-101.
26. Anzellotti P, Capone ML, Jeyam A, Tacconelli S, Bruno A, Tontodonati P, Di Francesco L, Grossi L, **Renda G**, Merciaro G, Di Gregorio P, Price TS, Garcia Rodriguez LA, Patrignani P. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum 2011;63(3):850-9.
27. **Renda G**, Zimarino M, Antonucci I, Tatasciore A, Ruggieri B, Bucciarelli T, Prontera T, Stuppia L, De Caterina R. Genetic determinants of blood pressure responses to caffeine drinking. Am J Clin Nutr 2012 Jan;95(1):241-8.
28. De Caterina R and **Renda G**. Clinical use of aspirin in ischemic heart disease: past, present and future. Curr Pharm Des 2012;18:5215-5223.
29. **Renda G** and De Caterina R. Measurements of thromboxane production and their clinical significance in coronary heart disease. Throm Haemost 2012;108:6-8.
30. Ricci F, **Renda G**, De Caterina R. Antithrombotic therapy in atrial fibrillation: state of the art and perspectives. G Ital Cardiol 2013;14(1):21-34.
31. De Caterina R, **Renda G**. Dabigatran as an alternative to warfarin for the prevention of thromboembolism in atrial fibrillation. G Ital Cardiol 2012;13(11 Suppl 1):19S-27S
32. Tatasciore A, Zimarino M, Tommasi R, **Renda G**, Schillaci G, Parati G, De Caterina R. Increased short-term blood pressure variability is associated with early left ventricular systolic dysfunction in newly diagnosed untreated hypertensive patients. J Hypertens 2013;31(8):1653-61.
33. **Renda G**, De Caterina R. The new oral anticoagulants in atrial fibrillation: once daily or twice daily? Vascul Pharmacol 2013 Sep-Oct;59(3-4):53-62.
34. De Caterina R, **Renda G**, Sanguolo R, Attena E, Di Lecce L, Romeo F; Steering Committee del Registro Europeo PREFER in AF. Management of thromboembolic risk in patients with atrial fibrillation in Italy: baseline data from the PREFER in AF European Registry. G Ital Cardiol 2014;15(2):99-109
35. Patti G, De Caterina R, Abbate R, Andreotti F, Biasucci LM, Calabrò P, Cioni G, Davì G, Di Sciascio G, Golia E, Golino P, Malatesta G, Mangiacapra F, Marcucci R, Nusca A, Parato VM, Pengo V, Prisco D, Pulcinelli F, **Renda G**, Ricottini E, Ruggieri B, Santilli F, Sofi F, Zimarino M; Working Group on Thrombosis of the Italian Society of Cardiology. Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper. Eur Heart J 2014;35(33):2213-23b.
36. De Caterina R, Ammentorp B, Darius H, Le Heuzey JY, **Renda G**, Schilling RJ, Schliephacke T, Reimitz PE, Schmitt J, Schober C, Zamorano JL, Kirchhof P; PREFER in AF Registry Investigators. Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. Heart 2014;100(20):1625-35.

37. **Renda G**, Committeri G, Zimarino M, Di Nicola M, Tatasciore A, Ruggieri B, Ambrosini E, Viola V, Antonucci I, Stuppia L, De Caterina R. Genetic determinants of cognitive responses to caffeine drinking identified from a double-blind, randomized, controlled trial. Submitted to Eur Neuropsychopharmacol 2015 Jun;25(6):798-807.
38. **Renda G**, Di Nicola M, De Caterina R. Net clinical benefit of non-vitamin K antagonist oral anticoagulants versus warfarin in phase III atrial fibrillation trials. Am J Med. 2015;128(9):1007-1014.
39. Marcovecchio ML, Gravina M, Gallina S, D'Adamo E, De Caterina R, Chiarelli F, Mohn A, **Renda G**. Increased left atrial size in obese children and its association with insulin resistance: a pilot study. Eur J Pediatr 2015 Aug 15 [Epub ahead of print].
40. De Innocentiis C, Caputi CG, Pinto F, Quintiliani S, Meccariello A, **Renda G**, Di Nicola M, De Caterina R, D'Attilio M. Failure in evoking the trigeminal cardiac reflex by mandibular stretching in healthy volunteers. Arch Ital Biol 2015;153(1):25-36.
41. De Caterina R, Andersson U, Alexander JH, Al-Khatib SM, Bahit MC, Goto S, Hanna M, Held C, Hohnloser S, Hylek EM, Lanus F, Lopes RD, López-Sendón J, **Renda G**, Horowitz J, Granger CB, Wallentin L; ARISTOTLE Investigators. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J 2016;175:175-83.
42. **Renda G**, Patti G, Sangiuolo R, Attena E, Malpezzi MG, De Caterina R; a nome dello Steering Committee del Registro Europeo PREFER in AF. Management of thromboembolic risk in patients with atrial fibrillation in Italy: follow-up data from the PREFER in AF European Registry. G Ital Cardiol 2016;17(11):922-931.
43. **Renda G**, Zimarino M, Ricci F, Piccini JP, Ezekowitz MD, Patel MR, Cappato R, Giugliano RP, De Caterina R. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. Am J Med 2016;129(10):1117-1123.
44. Patti G, Pengo V, Marcucci R, Cirillo P, **Renda G**, Santilli F, Calabrò P, De Caterina AR, Cavallari I, Ricottini E, Parato VM, Zoppellaro G, Di Gioia G, Sedati P, Cicchitti V, Davi G, Golia E, Pariggiano I, Simeone P, Abbate R, Prisco D, Zimarino M, Sofi F, Andreotti F, De Caterina R; Working Group of Thrombosis of the Italian Society of Cardiology. The left atrial appendage: from embryology to prevention of thromboembolism. Eur Heart J 2017;21;38(12):877-887.
45. Patti G, Lucerna M, Cavallari I, Ricottini E, **Renda G**, Pecan L, Romeo F, Le Heuzey J, Zamorano J, Kirchhof P, and De Caterina R. Insulin-requiring versus non-insulin requiring diabetes and thromboembolic risk in patients with atrial fibrillation: a PREFER in AF. J Am Coll Cardiol 2017;69(4):409-419.
46. De Caterina R, **Renda G**, Carnicelli A, Nordio F, Trevisan, Mercuri M, Ruff C, Antman E, Braunwald E, and Giugliano R. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. J Am Coll Cardiol 2017;69(11):1372-1382.
47. **Renda G**, Ricci F, Giugliano R, De Caterina R. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. J Am Coll Cardiol 2017;69(11):1363-1371.
48. Carnicelli AP, De Caterina R, Halperin JL, **Renda G**, Ruff CT, Trevisan M, Nordio F, Mercuri MF, Antman E, Giugliano RP; ENGAGE AF-TIMI 48 Investigators. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation 2017;135(13):1273-1275.
49. **Renda G**, Ricci F, De Caterina R. Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation: An Updated Meta-analysis. Am J Med 2017;130(4):457-461.
50. Pescetelli I, Genovesi E, **Renda G**, Di Renzo E, De Caterina R. Intracardiac thrombi during warfarin anticoagulation – A case report and a brief literature review. Cor et Vasa 2017;3:e277-e281.
51. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
52. De Caterina R, Brüggengjürgen B, Darius H, Köhler S, Lucerna M, Pecan L, **Renda G**, Schilling RJ, Schliephacke T, Zamorano JL, Le Heuzey JY, Kirchhof P. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. Arch Cardiovasc Dis 2018;111(2):74-84.
53. Siller-Matula JM, Pecan L, Patti G, Lucerna M, Kirchhof P, Lesiak M, Huber K, Verheugt FWA, Lang IM, **Renda G**, Schnabel RB, Wachter R, Kotecha D, Sellal JM, Rohla M, Ricci F, De Caterina R; TEAM in AF group. Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. Int J Cardiol 2018 Aug 15;265:141-147.
54. **Renda G**, De Caterina R. Sex Implications in the Response to Anticoagulant Therapy in Atrial Fibrillation. J Am Coll Cardiol 2018;72(3):283-286.
55. Kotecha D, Pollack CV Jr, De Caterina R, **Renda G**, Kirchhof P. Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin. J Am Coll Cardiol 2018 Oct 16;72(16):1984-1986.
56. Patti G, Pecan L, Lucerna M, Huber K, Rohla M, **Renda G**, Siller-Matula J, Schnabel RB, Cemin R, Kirchhof P, De Caterina R. Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATION registries. Int J Cardiol 2018 Nov 1;270:160-166.
57. Ricci F, Sutton R, Palermi S, Tana C, **Renda G**, Gallina S, Melander O, De Caterina R, Fedorowski A. Prognostic significance of non-cardiac syncope in the general population: a systematic review and meta-analysis. Cardiovasc Electrophysiol 2018 Dec;29(12):1641-1647.
58. Patti G, Cavallari I, Andreotti F, Calabrò P, Cirillo P, Denas G, Galli M, Golia E, Maddaloni E, Marcucci R, Parato VM, Pengo V, Prisco D, Ricottini E, **Renda G**, Santilli F, Simeone P, De Caterina R; Working Group on Thrombosis of the Italian Society of Cardiology. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nat Rev Cardiol 2019 Feb;16(2):113-130.

59. Patti G, Pecen L, Lucerna M, Huber K, Rohla M, **Renda G**, Siller-Matula J, Ricci F, Kirchhof P, De Caterina R. Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. *Am J Med* 2019 Jun;132(6):749-757
60. **Renda G**, Patti G, Lang IM, Siller-Matula JM, Hylek EM, Ambrosio G, Haas S, De Caterina R; Working Group on Thrombosis of the Italian Society of Cardiology. Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies. *Int J Cardiol* 2019 Jul 1;286:198-207. Review.
61. Patti G, Sticchi A, Pasceri V, Ricci F, **Renda G**, Hamrefors V, Melander O, Sutton R, Engström G, De Caterina R, Fedorowski A. The co-predictive value of a cardiovascular score for CV outcomes in diabetic patients with no atrial fibrillation. *Diabetes Metab Res Rev* 2019 Jul;35(5):e3145.
62. Calabrò P, Gragnano F, Cesaro A, Pariggiano I, Patti G, Cavallari I, Parato VM, **Renda G**, De Caterina R; a nome del Gruppo di Studio sulla Trombosi della Società Italiana di Cardiologia. [Atrial and left atrial appendage thrombosis in patients with atrial fibrillation: from pathophysiology to treatment]. *G Ital Cardiol* 2019 Jun;20(6):374-383.
63. Pietrangelo T, Doria C, Bondi D, Kinel E, **Renda G**, Neri G, Fanò-Illic G, Verratti V. Effects of endurance, resistance and neuro-muscular electrical stimulation trainings to the anthropometric and functional mobility domains in elderly. *Journal of Gerontology and Geriatrics* 2019;67(3):148-155.
64. **Renda G**, Ricci F, Patti G, Aung N, Petersen SE, Gallina S, Hamrefors V, Melander O, Sutton R, Engstrom G, Caterina R, Fedorowski A. CHA2DS2VASc score and adverse outcomes in middle-aged individuals without atrial fibrillation. *Eur J Prev Cardiol* 2019 Dec;26(18):1987-1997.
65. Patti G, Di Martino G, Ricci F, **Renda G**, Gallina S, Hamrefors V, Melander O, Sutton R, Engström G, De Caterina R, Fedorowski A. Platelet Indices and Risk of Death and Cardiovascular Events: Results from a Large Population-Based Cohort Study. *Thromb Haemost* 2019 Nov;119(11):1773-1784.
66. Lombardi M, Molisana M, Genovesi E, De Innocentiis C, Limbruno U, Misuraca L, Moretti L, Di Vito L, Di Nicola M, Zimarino M, **Renda G**, De Caterina R. Prevention of contrast-induced nephropathy with urine alkalization: the TEATE study design. *J Cardiovasc Med* 2020 Jan;21(1):65-72.
67. Ricci F, De Innocentiis C, Verrengia E, Ceriello L, Mantini C, Pietrangelo C, Irsuti F, Gabriele S, D'Alleva A, Khanji MY, Aung N, **Renda G**, Cameli M, Petersen SE, Cesare ED, Gallina S. The Role of Multimodality Cardiovascular Imaging in Peripartum Cardiomyopathy. *Front Cardiovasc Med* 2020 Feb 18;7:4.

Book Chapters

68. Patrono C, Cipollone F, **Renda G**, Patrignani P. Cyclooxygenase enzymes in human vascular disease. In *Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential*, by JR Vane, Kluwer Academic Publishers, William Harvey Press, London, UK, 1997, pp 73-78.
69. Patrignani P, Padovano R, Sciulli MG, Santini G, Panara MR, Rotondo MT, **Renda G**, and Patrono C. Mechanisms of Isoprostane Biosynthesis in humans. In *Eicosanoids, Aspirin and Asthma*, by A Szczeldik, R Gryglewski and JR Vane, Marcel Dekker Publisher, Inc, New York, USA, 1998, pp 77-89.
70. De Caterina R, **Renda G**. Atrial fibrillation – anti-thrombotic therapy. In *Therapeutic Strategies in Thrombosis*, by SD Kristensen, R De Caterina, DJ Moliterno. Clinical Publishing, Oxford, UK, 2006:275-300.
71. Butchart EG, Gohlke-Bärwolf C, **Renda G** and De Caterina R. Antithrombotic management. In *Heart valve disease. A guide to patient management after surgery*, by EG Butchart, C Gohlke-Bärwolf, MJ Antunes, RJC Hall, Informa Healthcare, United Kingdom, 2006:83-109.
72. De Caterina R, **Renda G**, Zimarino M. Terapia dell'infarto miocardico e delle sindromi coronariche. In *Trattato di farmacologia e terapia. Farmacoterapia cardiovascolare*, di E Tremoli, L Clabresi, G Franceschini e C Sirtori. UTET, Milano, Italy, 2006, pp 294-328.
73. **Renda G**, Zimarino M, De Caterina R. Dual antiplatelet strategies in patients requiring vitamin K antagonists. In *A Clinical Guide to the use of Antithrombotic Drugs in Coronary Artery Disease*, edited by Angiolillo DJ, Kastrati A and Simon D. Informa UK Limited (Informa Healthcare), UK, 2007; 28:251-262.
74. De Caterina R, **Renda G**, Tatasciore A, Zimarino M. Cardiopatia ischemica cronica. In *Malattie del cuore e dei vasi*, di R De Caterina, C Dal Palù, G Finardi, A Venco. Ed Piccin Nuova Libreria, Padova 2009.
75. **Renda G** and De Caterina R. Impact of antiplatelet therapy in heart disease. *Adv Cardiol* 2012;47:5-19.
76. **Renda G** and De Caterina R. Impact of antiplatelet therapy in heart disease. In *Antiplatelet therapy in acute coronary syndromes and atrial fibrillation*, by Victor Serebruany and Dan Atar. S.Karger AG, Switzerland, 2012;5-19.
77. De Caterina R, **Renda G**. Atrial fibrillation: current and forthcoming antithrombotic therapies. In *Therapeutic Advances in Thrombosis*, by David J. Moliterno, Steen Dalby Kristensen, Raffaele De Caterina, and Julie Hoffmann. Blackwell Publishing Ltd, 2013:285-305.
78. **Renda G**, De Caterina R. Coffee and Hypertension: A Focus on Contrasting Acute and Chronic Effects and Nutrigenetics. In *Coffee in Health and Disease Prevention*. Elsevier. 2015:395-402.
79. **Renda G**, Salerni S, De Caterina R. La fibrillazione atriale: diagnosi, classificazione e terapia anticoagulante. In *Aggiornamenti in Medicina Vascolare*. Editore: Enrico Agabiti-Rosei. 2015: 165-179.
80. Tofalo R, **Renda G**, De Caterina R, Suzzi G. Coffee Health effects. In *Encyclopedia of Food and Health* (1stEd.) Edited by Caballero B, Finglas P, Toldrá F (Elsevier). 2015:237-243.
81. **Renda G**, De Caterina R. Caffeine. In Principles of Nutrigenetics and Nutrigenomics: Fundamentals of Individualized Nutrition. Ed. By De Caterina R, Martinez AJ, Kohlmeier M (Elsevier) 2019:335-340.

SCOPUS PARAMETERS


Journal articles: 66 (44 in the last 10 years – 2010-2020)

H-index: 23

Number of citations: 3450

02 April 2020

Giulia Renda

A handwritten signature in black ink, appearing to read 'Giulia Renda', written in a cursive style.